Related Experiment Video
Updated: Sep 16, 2025
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Expanding the Patient Pool for Rilonacept
Emma St John1, Jessica R Carey1, Tanya Wilcox1
1University of Utah Health, Salt Lake City, Utah, USA.
None:
Recurrent pericarditis complicates 15%-30% of acute pericarditis cases despite initial anti-inflammatory treatment. The RHAPSODY trial (Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis) showed rilonacept, an interleukin-1 cytokine trap, to be an effective therapeutic option for patients with pericarditis recurrence. This case series demonstrates the utility and challenges of rilonacept use in the types of patients excluded from RHAPSODY.
